Anti-CD38 Antibody Subcutaneous Formulation for Reduced Volume
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD38 antibodies for treating CD38-associated diseases require high doses due to binding to red blood cells, leading to large volumes for subcutaneous administration and causing adverse effects like hemolytic anemia and infusion-related reactions.
Innovation Solution
Development of a subcutaneously administered anti-CD38 antibody with specific variable heavy and light chain regions, allowing for effective treatment with reduced adverse events and lower volumes, formulated for subcutaneous administration in doses ranging from 45 to 1,800 milligrams.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of anti-CD38 antibodies are administered to achieve therapeutic efficacy, then treatment effectiveness is improved, but the volume of administration increases and causes adverse effects like hemolytic anemia and infusion-related reactions
Solution Approach 1:
The patent applies local quality by engineering the antibody molecule with specific modifications: human IgG1 constant region to reduce immunogenicity, specific CDR sequences for optimized CD38 binding, and controlled affinity characteristics. These localized molecular modifications enable the antibody to achieve therapeutic efficacy at lower doses without causing hemolytic anemia or infusion-related reactions that plague conventional anti-CD38 antibodies
Solution Approach 2:
The patent employs parameter changes by optimizing the antibody's affinity constant (Kd) to fall within a specific range (10^-9 to 10^-11 M), adjusting the dose range to 45-1800 mg, and formulating at concentrations of 10-100 mg/mL. These parameter optimizations allow subcutaneous administration at volumes ≤1 mL while maintaining therapeutic efficacy and reducing adverse effects compared to conventional antibodies requiring much higher doses
2Reliability
If high doses of anti-CD38 antibodies are administered to overcome binding to red blood cells, then target saturation is improved, but the volume required for subcutaneous administration increases
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's affinity constant (Kd) to fall within 10^-9 to 10^-11 M, which enhances binding efficiency to CD38 targets. This optimized affinity parameter enables effective target saturation at lower doses (45-1800 mg) compared to conventional antibodies, thereby reducing the subcutaneous administration volume to ≤1 mL while maintaining adequate target engagement
Solution Approach 2:
The patent employs composite material design by combining human IgG1 constant region with specifically engineered variable regions containing optimized CDR sequences. This composite molecular structure achieves both high affinity binding to CD38 and reduced immunogenicity, enabling effective target saturation at lower volumes suitable for subcutaneous administration
3Reliability
If conventional anti-CD38 antibodies are administered intravenously to achieve sufficient dosing, then therapeutic coverage is improved, but patient convenience and ease of administration deteriorates
Solution Approach 1:
The patent applies parameter changes by formulating the antibody at high concentrations (10-100 mg/mL) suitable for subcutaneous injection, optimizing the dose range (45-1800 mg) for home administration, and engineering the molecule for reduced immunogenicity. These parameter optimizations enable convenient subcutaneous administration at volumes ≤1 mL, improving patient convenience while maintaining therapeutic coverage comparable to intravenous therapy
Solution Approach 2:
The patent extracts the problematic aspects of conventional anti-CD38 antibodies (high immunogenicity, low affinity requiring high doses, large formulation volumes) and replaces them with a redesigned antibody molecule having human IgG1 constant region, optimized CDR sequences for high affinity, and concentrated formulation. This extraction of harmful characteristics enables transition from inconvenient intravenous to convenient subcutaneous administration
Data Source
AI summary
Methods of administering isolated anti-CD38 antibodies subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies.